Recombinant expression vector, recombinant cell and medicine for treating vitiligo as well as preparation method and application of recombinant expression vector
By transfecting melanocytes with recombinant expression vectors and using the combination of mussel foot protein and tyrosinase, self-adhesion and recoloration of vitiligo skin were achieved, solving adverse reactions and uneven pigment recovery in existing treatment plans Problems significantly improve the safety and efficiency of treatment.
Patent Information
- Application Number
- CN202411163320.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-12-03
AI Technical Summary
The existing vitiligo treatment plan has problems such as adverse drug reactions, great treatment pain, and uneven pigment recovery. Especially, drugs and phototherapy have re-pigment loss in 60%-70% of patients within 1 year, and epidermal transplantation requires multiple surgeries. , the process is painful and the melanocytes are unevenly distributed.
Melanocytes were transfected by liposome method using the recombinant expression vector pEGFP-N1-PD-L1-linker-mcofp-3 to prepare a suspension of adhesion melanocytes, using the binding of mussel foot silk protein and tyrosinase. Promotes melanocyte adhesion and recoloration of skin wounds.
The strong wet adhesion of mussel foot silk protein and the extramembrane expression characteristics of PD-L1 enable melanocytes to self-adhese and reduce inflammatory reactions. Tyrosinase catalyzes the formation of melanin from dopa, significantly improving the complex color effect of vitiligo skin and reducing Treat pain and frequency.
Smart Images

Figure CN119061064A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology, and specifically relates to a recombinant expression vector, a recombinant cell, a medicine for treating vitiligo, and a preparation method and application thereof. Background Art
[0002] Vitiligo is a common acquired depigmentation disease caused by the reduction or complete loss of functional melanocytes in the skin and (or) hair follicles. Clinically, it is mainly manifested by hypopigmented spots and (or) depigmented patches without subjective symptoms. So far, the etiology and pathogenesis of vitiligo have not been elucidated. At present, the main treatment options for vitiligo are drugs, phototherapy and epidermal transplantation. Among them, drugs and phototherapy have certain limitations and adverse reactions (such as skin atrophy, rash, etc.). Many patients find it difficult to adhere to treatment due to adverse drug reactions. Regardless of phototherapy or topical medications, 60%-70% of patients still have the re-pigmented area restored within 1 year. Epidermal transplantation is to remove a part of normal skin from healthy skin and then transplant it to the diseased white spot area. The transplantation ratio is generally greater than 1:1. Patients with large areas of white spots need to undergo repeated transplantation operations many times, and the process is painful. At present, there are studies that replace traditional epidermal transplantation with tissue engineering epidermal culture to achieve the expansion of skin area from small to large, which solves the problem of large-area skin removal during transplantation. Tissue engineering epidermis is mainly composed of keratinocytes and melanocytes. The keratinocytes play a role in fixing melanocytes. Since the number of melanocytes and keratinocytes extracted from the skin is very different, melanocytes are not only small in number, but also have a significantly lower proliferation rate than keratinocytes. Therefore, the tissue-engineered epidermis formed by the co-culture of the two has a serious problem of uneven distribution of melanocytes, resulting in uneven pigmentation of the depigmented patches in a single treatment, requiring multiple dermabrasion treatments. Therefore, it is urgent to develop a safe, efficient and less painful vitiligo treatment program. Summary of the invention
[0003] The purpose of the present invention is to provide a recombinant expression vector, a recombinant cell, a medicine for treating vitiligo, and a preparation method and application thereof.
[0004] To solve the above-mentioned purpose, the present invention adopts the following technical solution: A recombinant expression vector pEGFP-N1- PD-L1-linker-mcofp-3 The recombinant expression vector pEGFP-N1- PD-L1-linker-mcofp-3 To fusion gene PD-L1-linker-mcofp-3 Inserted into the restriction site EcoRI / BamHI of the vector pEGFP-N1; The fusion gene PD-L1-linker-mcofp-3 The nucleotide sequence is shown in SEQ ID NO.1.
[0005] The above-mentioned recombinant expression vector pEGFP-N1- PD-L1-linker-mcofp-3 , the fusion gene PD-L1- linker-mcofp-3 The amino acid sequence of the encoded protein is shown in SEQ ID NO.2.
[0006] A recombinant cell, the recombinant cell comprising a recombinant expression vector pEGFP-N1- PD-L1-linker-mcofp- 3 .
[0007] The above recombinant cells are MC-pEGFP-N1- PD-L1-linker-mcofp-3 , which is the recombinant expression vector pEGFP-N1- PD-L1-linker-mcofp-3 Obtained by transfection into melanocytes using liposome method.
[0008] The above recombinant expression vector pEGFP-N1- PD-L1-linker-mcofp-3 , and the use of the above-mentioned recombinant cells in the preparation of drugs for treating vitiligo.
[0009] A drug for treating vitiligo, comprising the above-mentioned recombinant cell MC-pEGFP-N1- PD-L1- linker-mcofp-3 .
[0010] The preparation method of the above-mentioned drug comprises the following steps: PD-L1-linker- mcofp-3 The cells were cultured in cnt40 medium containing 0.5 μmoL / L glutathione. When the cell confluence reached 80%, the cells were washed with normal saline, the cells were digested, and the digestion was terminated. The cells were collected by centrifugation, resuspended with sterile oxygen-dissolved saline, tyrosinase was added at a final concentration of 1000U / mL, and incubated at 37°C for 30 minutes to obtain a self-adhesive melanocyte suspension, which is the drug for treating vitiligo.
[0011] The amount of dissolved oxygen in the sterile oxygen-dissolved saline is 8-10 mg / L.
[0012] In the present invention mcofp-3The gene-expressed mussel foot silk protein contains a high content of DOPA. Under the action of tyrosinase and high dissolved oxygen salt solution, the redox activity of mussel foot silk protein rich in DOPA groups is driven, so that the mussel foot silk protein is deposited and bound to the surface of the target matrix, generating a strong surface interaction. Melanocytes themselves contain tyrosinase. In order to prevent the tyrosinase in the melanocytes from prematurely catalyzing the DOPA group of mussel foot silk protein, glutathione is added during the melanocyte culture process. After the sulfhydryl group on the amino acid of glutathione enters the cell, it can complex with the copper ion in tyrosinase to prevent the activation of tyrosinase, thereby keeping the mussel foot silk protein DOPA in a free state without being catalyzed, and avoiding the formation of adhesion between the mussel foot silk protein and the culture bottle. After a sufficient number of melanocyte suspensions are obtained through culture, tyrosinase is added to the high dissolved oxygen saline to catalyze the free DOPA, and the cell suspension is applied to the wound of the vitiligo patient for a certain period of time, so that the melanocytes can effectively adhere to the moist wound.
[0013] The beneficial effects of the present invention are: (1) Mussel byssin is a non-cellular tissue formed by the byssin secreted by the foot tissue of the marine organism mussel. It has extremely strong wet adhesion ability in water environment and is non-toxic, harmless and non-immunogenic to the human body. It has good biocompatibility and degradability and does not hinder the spontaneous healing of human tissue.
[0014] (2) By mcofp-3 Add transmembrane protein before the gene fragment PD-L1 The gene enables mussel foot silk protein to be expressed extracellularly on melanocytes, giving melanocytes the property of self-adhesion. In addition, PD-L1 can inhibit macrophages from secreting pro-inflammatory factors such as TNF-α and IL-1, and can participate in inflammation regulation. Therefore, when melanocytes expressing this protein act on wounds, they can reduce the body's inflammatory response to a certain extent, which is beneficial to wound recovery.
[0015] (3) The tyrosinase added in the present invention has a dual catalytic effect. While catalyzing the redox of extracellular mussel foot silk protein DOPA to play an adhesion role, it also acts on the tyrosine synthesized in the melanocyte itself, so that tyrosine is hydroxylated into DOPA under the action of tyrosinase, and then oxidized into dopaquinone; dopaquinone is a melanin precursor. The melanin precursor further forms melanin deposits on the skin during the metabolism of melanocytes, thereby enhancing the ability of melanocytes to form melanin and effectively improving the re-pigmentation effect of vitiligo-bleached skin. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 : Schematic diagram of the structure of the fusion gene.
[0017] Figure 2 : Schematic diagram of the structure of the recombinant expression vector.
[0018] Figure 3 : Enzyme digestion results of recombinant expression vector.
[0019] Figure 4 : Flow cytometry analysis of the efficiency of recombinant expression vector transfection into melanocytes.
[0020] Figure 5 :The results of flow cytometric analysis of melanocytes expressing fusion protein.
[0021] Figure 6 : Before and after comparison of the facial area of white spots in a vitiligo patient 3 weeks after treatment. DETAILED DESCRIPTION
[0022] In order to make the content of the present invention easier to understand, the technical solution of the present invention is further described in detail below in conjunction with specific embodiments. However, the present invention is not limited thereto.
[0023] The experimental materials involved in the following embodiments are as follows: pEGFP-N1 plasmid was purchased from Core Biotechnology, catalog number kl-zl-1068; 1× Geneticin was purchased from Gibco, catalog number 2309571; cnt40 culture medium was purchased from Cellntec, catalog number 2007225; Lipofectamine™ 2000 transfection reagent was purchased from ThermoFisher, catalog number 11668019; glutathione was purchased from QASEG, CAS number 70-18-8; APC-MouseAnti-Human-CD274 monoclonal antibody, APC-MouseIgG2b, k Isotype Control monoclonal antibody were purchased from Lianke Biotechnology; tyrosinase was purchased from Solebao, catalog number T8830; EcoRI was purchased from Thermo Scientific™, catalog number ER0271; BamHI was purchased from Thermo Scientific™, catalog number ER0055; MEM medium was purchased from Gibco, catalog number C12571500CP; type I collagenase base was purchased from Gibco, catalog number 17100; triple antibody reagent was purchased from Gibco, catalog number 15240-062.
[0024] Example 1 pEGFP-N1- PD-L1 - linker - mcofp -3 Construction, screening, amplification and identification of recombinant expression vectors (1) PD-L1 Genes are linked to mcofp-3 Gene ligation to form a fusion gene encoding PD-L1-linker-mCofp-3 fusion protein (Figure 1 ), the amino acid sequence of the PD-L1-linker-mcofp-3 fusion protein is shown in SEQ ID NO.2, and the nucleotide sequence of the fusion gene is shown in SEQ ID NO.1.
[0025] Shanghai Bioengineering was commissioned to synthesize the fusion gene encoding the PD-L1-linker-mcofp-3 fusion protein and insert it into the EcoRI / BamHI restriction site of the pEGFP-N1 vector to construct the recombinant expression vector pEGFP-N1- PD-L1 - linker- mcofp -3 ( Figure 2 ).
[0026] (2) Place the EP tube containing 100 μL DH5α competent cells in an ice bath. After the DH5α competent cells melt, add 2 μL of the recombinant expression vector pEGFP-N1- PD-L1 - linker-mcofp -3, gently mix and place in an ice bath for 30 min, then place in a 42 ℃ water bath for heat shock for 90 s, and immediately place in an ice bath for cooling for 5 min. Add 400 μL of LB liquid medium without resistance to the EP tube, mix and place in a shaker (37 ℃, 45 r / min) for 1 h to allow the DH5α competent cells to resume normal growth and express the kanamycin antibiotic resistance gene encoded by the plasmid. Spread 400 μL of LB liquid medium containing the above DH5α competent cells on an LB plate containing 30 ug / mL kanamycin and culture in a 37 ℃ incubator for 48 h to obtain positive clones. Pick a single colony and transfer it to 5 mL of LB liquid culture medium containing 30 ug / mL kanamycin. Incubate it in a 37 ℃ incubator for 16 h until the bacterial solution becomes turbid. Take 5 mL of the culture solution for plasmid extraction and perform double enzyme digestion with EcoRI and BamHI. The enzyme digestion product is detected after 0.8% agarose gel electrophoresis. Figure 3 As shown, there is an amplified band between 700 and 800 bp, which is consistent with the designed fusion gene size of about 778 bp, indicating that the fusion gene has been successfully cloned into the eukaryotic expression vector pEGFP-N1.
[0027] Example 2 Extraction and culture of melanocytes (1) Four healthy full-thickness inner thigh tissue slices (0.5×0.8 cm) provided by volunteers were removed from tissue protection solution (MEM culture medium and triple antibody reagent prepared in a volume ratio of 50:1) and immersed in 95% alcohol for 1 min. After the tissue was removed, it was washed with saline to remove the alcohol, and the connective tissue and adipose tissue of the cortex were removed with forceps and scissors.
[0028] (2) Wash the cortical tissue obtained in step (1) seven times with physiological saline, chop it with scissors and place it in a 60 mm dish. Add 4 mL of 0.1% type I collagenase and digest it in a shaking incubator at 37°C overnight. Then add 1 ml of 0.25% trypsin and digest it in a shaking incubator at 37°C for about 2 h until most of the cells on the shredded cortex are digested. Then add 1 ml of FBS to terminate the digestion and obtain a cell suspension.
[0029] (3) The cell suspension obtained in step (2) was passed through a 70 μm cell sieve and centrifuged at 500 g for 5 min. The supernatant was discarded and the cell pellet was collected. Physiological saline was added to the cell pellet to resuspend it. After mixing, a sample was taken and the total number of cells was counted to be 3.1×10 6 Two experimental groups were set up, group A was a blank control group in which melanocytes were not transfected with the recombinant expression vector, and group B was a group in which melanocytes were transfected with the recombinant expression vector pEGFP-N1- PD-L1 - linker-mcofp -3 experimental group; melanocytes were inoculated with cnt40 medium containing 0.1 mg / mL geneticin, and the inoculation number was 8×10 5 Each well has a volume of 2 mL and is cultured in a 37°C incubator. Geneticin in the culture medium can inhibit the growth of keratinocytes and fibroblasts.
[0030] (4) Replace the cnt40 medium containing 0.1 mg / mL geneticin every 3 days and continue culturing in a 37°C incubator until the 7th day to obtain pure melanocytes. On the 10th day, the melanocyte fusion degree can reach 80%.
[0031] Example 3: In vitro transfection of melanocytes with the recombinant expression vector using liposomes (1) In a sterile EP tube, add 3 μg of the recombinant expression vector pEGFP-N1- PD-L1 - linker-mcofp -3, dilute with 150 μL of serum-free and antibiotic-free MEM medium and mix gently.
[0032] (2) In a sterile EP tube, add 150 μL of serum-free and antibiotic-free MEM medium to 15 μL of Lipofectamine™ 2000 transfection reagent and gently mix.
[0033] (3) Gently mix the two tubes of reagents and incubate at room temperature for 5 min to obtain the recombinant expression vector-liposome complex.
[0034] (4) When the confluency of the melanocytes cultured in group B in step (4) of Example 2 reached 80%, the old culture medium was discarded and the cells were washed twice with PBS; 250 μL of the recombinant expression vector-liposome complex was added to each well, and the culture plate was shaken back and forth to evenly distribute the complex on the surface of the melanocytes, and incubated in a 37°C incubator for 6 h. Then, the cells were washed with cnt40 culture medium to remove the untransfected complex, and 2 mL of cnt40 culture medium containing 0.5 μmoL / L glutathione was added to each well, and the cells were cultured in a 37°C, 5% CO2 incubator for 48 h. The control well A and the experimental well B were treated in the same manner.
[0035] (5) After 48 h of culture, the cells were washed twice with saline and digested with 1 mL of 0.05% trypsin for 3 min. The digestion was terminated with 1 mL of cnt40 medium. The cell pellet was collected and counted by centrifugation at 500 g for 5 min. The number of melanocytes in group A was 3.0×10 6 The number of melanocytes in group B was 2.9×10 6 indivual.
[0036] (6) Resuspend the cell pellet in 45 ml of saline and take 1×10 6 The melanocytes were used for flow cytometry. The transduction efficiency was obtained by detecting the proportion of melanocytes containing green fluorescent protein EGFP by flow cytometry. The above two groups of cells were washed twice with PBS and then resuspended with 300 ul PBS. The results of quantitative analysis by flow cytometry were as follows: Figure 4 As shown, melanocytes in group A were used as the blank control group without transfection of the recombinant expression vector, and the flow cytometer could not detect the fluorescence of EGFP expression; melanocytes in group B were used as the recombinant expression vector transfection group, and the transduction efficiency was 80.10%, indicating that the recombinant expression vector pEGFP-N1- PD-L1 - linker-mcofp -3 successfully transfected melanocytes (MC), recombinant cells MC-pEGFP-N1- PD-L1 - linker-mcofp -3 was successfully constructed and expressed well, and can be used for subsequent experiments.
[0037] Example 4: Subculture and expansion of melanocytes and detection of protein expression by flow cytometry (1) The remaining 1.9×10 6The cells were resuspended in 5 mL of cnt40 medium containing 0.5 μmoL / L glutathione and inoculated into T25 culture flasks for passage and expansion in a 37°C, 5% CO2 incubator. After 4 days of culture, the cell confluence reached 80%. The cells were washed twice with saline, digested with 1 mL of 0.05% trypsin for 3 min, and digested with 1 mL of cnt40 medium. The cells were centrifuged at 500 g for 5 min, the supernatant was discarded, the cell pellet was collected and counted, and the number of cells was 8.2×10 6 indivual.
[0038] (2) Resuspend the cell pellet obtained in step (1) in 45 ml of normal saline and take 2×10 6 The cells were used for flow cytometry and washed twice with PBS before use.
[0039] Set up 2 experimental groups: T group test group: 10 μl APC-Mouse Anti-Human-CD274 monoclonal antibody was added to the above cells, incubated at room temperature for 30 min, PBS was added to mix, centrifuged at 500 g for 3 min, the supernatant was discarded, the cell pellet was collected, and 300 μl PBS was added to the cell pellet to resuspend it, and quantitative analysis was performed by flow cytometry.
[0040] Group C isotype control group: 10 μl APC-Mouse IgG2b,k Isotype Control monoclonal antibody was added to the above cells, incubated at room temperature for 30 min, added PBS to mix, centrifuged at 500 g for 3 min, discarded the supernatant, collected the cell pellet, and then added 300 μl PBS to the cell pellet for resuspending and quantitative analysis by flow cytometry.
[0041] The streaming results are as follows Figure 5 As shown, the fusion proteins embedded in the recombinant expression vector are PD-L1 (CD274) protein and mCofp-3 protein, both of which are expressed at the same time, so by detecting melanocyte CD274 + The positive expression rate of the fusion protein in melanocytes can be used to know the expression of the fusion protein in melanocytes. The experimental results show that the melanocyte surface marker CD274 + The positive expression rate was as high as 97.80%, indicating that successfully transfected melanocytes can well express the fusion protein on the recombinant expression vector.
[0042] Example 5 Application of self-adhesive melanocyte suspension in treating vitiligo (1) The remaining melanocytes in step (1) of Example 4 were centrifuged at 500 g for 5 min, the supernatant was discarded, and the cell pellet was collected; (2) After passing sterile pure oxygen into 200 ml of sterile saline for a period of time, 10 ml of the sterile saline was taken out to measure the dissolved oxygen content using a dissolved oxygen meter. This was repeated several times until the dissolved oxygen content reached 8 mg / L. The melanocyte precipitate from step (1) was resuspended in the 80 ml sterile saline to prepare a solution with a density of 1×10 5 Add tyrosinase to the melanocyte suspension at a final concentration of 1000 U / mL and incubate in a 37°C incubator for 30 min; (3) Use the dermabrasion machine on the vitiligo treatment device to grind the skin of the white spots of the vitiligo patient down to the dermis layer.
[0043] (4) The melanocyte suspension incubated in step (2) was centrifuged at 500 g for 5 min, the supernatant was discarded, the melanocyte precipitate was collected, and 80 ml of physiological saline was added to the melanocyte precipitate to resuspend it to a density of 1×10 5 / mL melanocyte suspension; keep the patient's wound horizontal, and immediately drop the melanocyte suspension onto the patient's wound, wait for 5 minutes, and let the melanocytes settle and adhere to the wound skin through mussel foot silk protein. Gently suck away the liquid from the wound, and gently apply polymyxin ointment to prevent bacterial infection on the wound, and finally bandage it with sterile oil gauze.
[0044] (5) Change the polymyxin ointment on the wound every three or four days. The wound will heal after three weeks. The recovery of the wound stains will be as follows: Figure 6 As shown in the figure, it can be observed that the white spots of the patients basically returned to normal skin color after treatment, indicating that the melanocyte suspension can successfully adhere to the wound and effectively improve the skin depigmentation.
Claims
1. A recombinant expression vector pEGFP-N1- PD-L1-linker-mcofp-3 , characterized in that: The recombinant expression vector pEGFP-N1- PD-L1-linker-mcofp-3 To fusion gene PD-L1-linker-mcofp-3 Inserted into the restriction site EcoRI / BamHI of the vector pEGFP-N1; The fusion gene PD-L1-linker-mcofp-3 The nucleotide sequence is shown in SEQ ID NO.
1.
2. The recombinant expression vector pEGFP-N1- according to claim 1 PD-L1-linker-mcofp-3 , characterized in that: The fusion gene PD-L1-linker-mcofp-3 The amino acid sequence of the encoded protein is shown in SEQ ID NO.
2.
3. A recombinant cell, characterized in that: The recombinant cell comprises the recombinant expression vector pEGFP-N1- PD-L1-linker-mcofp-3 .
4. The recombinant cell according to claim 3, characterized in that: The recombinant cell is MC-pEGFP-N1- PD-L1- linker-mcofp-3 , which is the recombinant expression vector pEGFP-N1- PD-L1-linker-mcofp-3 Obtained by transfection into melanocytes using liposome method.
5. The recombinant expression vector pEGFP-N1- according to any one of claims 1 to 2 PD-L1-linker-mcofp-3 , Use of the recombinant cell as described in any one of claims 3 to 4 in the preparation of a drug for treating vitiligo.
6. A drug for treating vitiligo, characterized in that: The drug comprises the recombinant cell MC-pEGFP-N1- PD-L1-linker-mcofp-3 .
7. The method for preparing the drug according to claim 6, characterized in that: The recombinant cells MC-pEGFP-N1- PD-L1- linker-mcofp-3 The cells were cultured in cnt40 medium containing 0.5 μmoL / L glutathione. When the cell confluence reached 80%, the cells were washed with normal saline, the cells were digested, and the digestion was terminated. The cells were collected by centrifugation, resuspended with sterile oxygen-dissolved saline, tyrosinase was added at a final concentration of 1000U / mL, and incubated at 37°C for 30 minutes to obtain a self-adhesive melanocyte suspension, which is the drug for treating vitiligo.
8. The preparation method according to claim 7, characterized in that: The amount of dissolved oxygen in the sterile oxygen-dissolved saline is 8-10 mg / L.
